LRRK2 as a therapeutic target in Parkinson's disease

European Journal of Neurology

Volumn 18, Issue 4, 2011, Pages 545-

  Tan, E K ^a,b   Schapira, A H ^c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; ALPHA SYNUCLEIN; GUANOSINE TRIPHOSPHATASE; INDIRUBIN 3' MONOAMINEE; LEUCINE RICH REPEAT KINASE 1; LEUCINE RICH REPEAT KINASE 2; MYELIN BASIC PROTEIN; PARKIN; PINK1 PROTEIN; PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

AGING; AMPLICON; AUTOPHOSPHORYLATION; BLOOD BRAIN BARRIER; CELL DAMAGE; CELL DEATH; CENTRAL NERVOUS SYSTEM; CRYSTAL STRUCTURE; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ETHNIC DIFFERENCE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HERPES SIMPLEX VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEWY BODY; MOLECULAR WEIGHT; NERVE CELL CULTURE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANTIPARKINSON AGENTS; ENZYME INHIBITORS; HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 79952714278     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03305.x     Document Type: Editorial

References (18)

1. Tan EK, Schapira AH. New LRRK2 variants identified in Parkinson's disease. Eur J Neurol 2011; 18: 369-370.
2. Schapira AH. The importance of LRRK2 mutations in Parkinson disease. Arch Neurol 2006; 63: 1225-1228.
3. Abdalla-Carvalho CB, Santos-Rebouças CB, Guimarães BC, et al. Genetic analysis of LRRK2 functional domains in Brazilian patients with Parkinson's disease. Eur J Neurol 2010; 17: 1479-1481.
4. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007; 28: 641-653.
5. Tan EK, Zhao Y, Skipper L, et al. The lrrk2 gly2385arg variant is associated with parkinson's disease: genetic and functional evidence. Hum Genet 2007; 120: 857-863.
6. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005; 102: 16842-16847.
7. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant lrrk2 mediates neuronal toxicity. Nat Neurosci 2006; 9: 1231-1233.
8. Lu YW, Tan EK. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. J Neurosci Res 2008; 86: 1895-1901.
9. Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010; 16: 998-1000.
10. Li Y, Liu W, Oo TF, et al. Mutant lrrk2 (r1441g) bac transgenic mice recapitulate cardinal features of parkinson's disease. Nat Neurosci 2009; 12: 826-828.
11. Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009; 29: 11257-11262.
12. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol. 2010; 6: 309-317.
13. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008; 7: 97-109.
14. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW. Mitofusin-1 and Mitofusin-2 are ubiquitinated in a PINK1/parkin dependent manner upon induction of mitophagy. Hum Mol Genet 2010; 19: 4861-4870.
15. Dagda RK, Cherra SJ III, Kulich SM, Tandon A, Park D, Chu CT. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem. 2009; 284: 13843-13855.
16. Whitworth AJ, Pallanck LJ. The PINK1/Parkin pathway: a mitochondrial quality control system? J Bioenerg Biomembr 2009; 41: 499-503.
17. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 2008; 105: 1499-1504.
18. Sheng D, Qu D, Kwok KH, et al. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet. 2010; 6: e1000914.